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Clinical beneﬁt of vedolizumab on articular
manifestations in patients with active
spondyloarthritis associated with inﬂammatory
bowel disease
Vedolizumab (VDZ) is a new biological agent which was
recently approved for the treatment of inﬂammatory bowel
disease (IBD)1 following the good clinical responses reported by
clinical trials for both Crohn’s disease2 and ulcerative colitis.3
However, the effects of VDZ on extraintestinal manifestations
were not reported in these trials, and the ‘real life’ experience is
still limited. On these premises, we read with interest the recent
work by Varkas et al4 reporting a series of ﬁve patients with
IBD who were treated with VDZ and promptly developed new
onset or exacerbation of spondyloarthritis (SpA), irrespective of
the response to treatment on intestinal symptoms. Although the
hypotheses proposed by the authors to explain such events
sound reasonable, we would like to report our different prelim-
inary results on the effect of VDZ on IBD-associated SpA. From
June to December 2016, a treatment with VDZ was started in
53 patients. Data were collected prospectively. Patient character-
istics and main results are shown in table 1. Notably, 81.1% of
patients had been previously treated with at least one TNF-α
inhibitor, and almost all (96.2%) were steroid dependent.
Overall, 36 out of 53 patients (67.9%) completed the induction
phase at last observation, and the mean follow-up of the entire
cohort was 2.6±1.6 months. Eight (15.1%) patients had a
history of IBD-associated SpA but were inactive at the time of
initiation of VDZ, whereas 14 (26.4%) had active SpA when
VDZ was started. First, no case of induction or ﬂare of arthritis
and/or sacroiliitis was reported among the entire cohort, includ-
ing the patients without a prior SpA diagnosis. Second, 6 out of
the 14 patients with active SpA (46.2%)—all complaining of
peripheral arthropathy—experienced a sharp clinical beneﬁt
after the initiation of VDZ. About gut inﬂammation of these six
patients, three of them were in clinical remission after 6 and
12 weeks of therapy, two were in remission after 6 weeks (they
have not reached week 12 yet) and one patient did not experi-
ence any response on intestinal symptoms after 14 weeks of
treatment. As a consequence, our preliminary prospective data
indicate a potential beneﬁt of VDZ on IBD-associated SpA.
Even if we do not reject the possibility that VDZ may induce
new onset or exacerbation of arthritis and/or sacroiliitis, the pre-
vious demonstration of α4β7 in the joint5 6 and the recent evi-
dence of the upregulation of mucosal vascular address in cell
adhesion molecule (MadCAM-1) in the high endothelial venules
of bone marrow in patients with active axial SpA7 seem to
strengthen the hypothesis of a beneﬁcial rather than a paradox-
ical effect of α4β7 blockade on articular manifestations of IBD.
Obviously, more details about the molecular mechanisms under-
lying the α4β7 blockade in the joints are required, and large
cohort studies are needed to provide more evidence on these
preliminary ﬁndings.
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Table 1 Characteristics of patients and main results
Variable n=53
Age (years), mean±SD 51.5±15.7
Male gender, n (%) 28 (52.8)
Smokers, n (%)
Never 50 (94.3)
Current 2 (3.8)
Ex 1 (1.9)
Type of disease, n (%)
Crohn’s disease 34 (64.2)
Ulcerative colitis 19 (35.8)
Duration of disease (years), mean±SD 13.6±9.4
Localisation of the disease, n (%)
Crohn’s disease
Ileal 3 (8.8)
Ileocolic 26 (76.5)
Colic 4 (11.8)
Upper gastrointestinal tract* 1 (2.9)
Perianal disease 7 (20.6)
Ulcerative colitis
Proctitis 0 (0.0)
Left-sided 6 (31.6)
Extensive 13 (68.4)
Behaviour (Crohn’s disease), n (%)
Inflammatory 16 (47.1)
Stricturing 17 (50.0)
Fistulising 1 (2.9)
Previous resections (Crohn’s disease), n (%) 21 (61.8)
Previous biological treatments
Yes 43 (81.1)
No (naïve to biologics) 10 (18.9)
Steroid-dependent, n (%) 51 (96.2)
IBD-associated SpA
No history 31 (58.5)
History (inactive at initiation of VDZ) 8 (15.1)
Active at initiation of VDZ 14 (26.4)
Peripheral arthropathy 12 (85.7)
Axial and peripheral arthropathy 2 (14.3)
Clinical benefit on SpA following initiation of VDZ (n=14)
No clinical benefit 8/14 (57.1)
Improvement 6/14 (42.9)
New onset/exacerbation of SpA induced by VDZ 0
*In addition to an ileocolic localisation.
IBD, inflammatory bowel disease; SpA, spondyloarthritis; VDZ, vedolizumab.
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